These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 15606392)
1. The usual medical care for irritable bowel syndrome. Whitehead WE; Levy RL; Von Korff M; Feld AD; Palsson OS; Turner M; Drossman DA Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1305-15. PubMed ID: 15606392 [TBL] [Abstract][Full Text] [Related]
2. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Daley AJ; Grimmett C; Roberts L; Wilson S; Fatek M; Roalfe A; Singh S Int J Sports Med; 2008 Sep; 29(9):778-82. PubMed ID: 18461499 [TBL] [Abstract][Full Text] [Related]
3. Patients with irritable bowel syndrome in primary care appear not to be heavy healthcare utilizers. Faresjö A; Grodzinsky E; Foldevi M; Johansson S; Wallander MA Aliment Pharmacol Ther; 2006 Mar; 23(6):807-14. PubMed ID: 16556183 [TBL] [Abstract][Full Text] [Related]
4. Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients. Mearin F; Badía X; Balboa A; Benavent J; Caballero AM; Domínguez-Muñoz E; Garrigues V; Piqué JM; Roset M; Cucala M; Figueras M; Aliment Pharmacol Ther; 2006 Mar; 23(6):815-26. PubMed ID: 16556184 [TBL] [Abstract][Full Text] [Related]
5. Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Whitehead WE; Palsson OS; Levy RL; Feld AD; VonKorff M; Turner M Am J Gastroenterol; 2006 May; 101(5):1057-65. PubMed ID: 16573774 [TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129 [TBL] [Abstract][Full Text] [Related]
7. Functional bowel disorders in primary care: factors associated with health-related quality of life and doctor consultation. Lee V; Guthrie E; Robinson A; Kennedy A; Tomenson B; Rogers A; Thompson D J Psychosom Res; 2008 Feb; 64(2):129-38. PubMed ID: 18222126 [TBL] [Abstract][Full Text] [Related]
8. The value of a general therapeutic approach in subjects with irritable bowel syndrome. Monsbakken KW; Vandvik PO; Farup PG Aliment Pharmacol Ther; 2005 Jan; 21(1):21-7. PubMed ID: 15644041 [TBL] [Abstract][Full Text] [Related]
10. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Hungin AP; Chang L; Locke GR; Dennis EH; Barghout V Aliment Pharmacol Ther; 2005 Jun; 21(11):1365-75. PubMed ID: 15932367 [TBL] [Abstract][Full Text] [Related]
11. A course of instruction for women with irritable bowel syndrome. Bengtsson M; Ulander K; Börgdal EB; Christensson AC; Ohlsson B Patient Educ Couns; 2006 Jul; 62(1):118-25. PubMed ID: 16098703 [TBL] [Abstract][Full Text] [Related]
12. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. Bardhan KD; Forbes A; Marsden CL; Mason T; Short G Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702 [TBL] [Abstract][Full Text] [Related]
13. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040 [TBL] [Abstract][Full Text] [Related]
14. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Reilly MC; Barghout V; McBurney CR; Niecko TE Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674 [TBL] [Abstract][Full Text] [Related]
15. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Williams RE; Black CL; Kim HY; Andrews EB; Mangel AW; Buda JJ; Cook SF Aliment Pharmacol Ther; 2006 Jun; 23(11):1667-75. PubMed ID: 16696818 [TBL] [Abstract][Full Text] [Related]
16. Effect of nurse-led gut-directed hypnotherapy upon health-related quality of life in patients with irritable bowel syndrome. Smith GD J Clin Nurs; 2006 Jun; 15(6):678-84. PubMed ID: 16684163 [TBL] [Abstract][Full Text] [Related]
17. The general practitioner's approach to irritable bowel syndrome: from intention to practice. Bellini M; Tosetti C; Costa F; Biagi S; Stasi C; Del Punta A; Monicelli P; Mumolo MG; Ricchiuti A; Bruzzi P; Marchi S Dig Liver Dis; 2005 Dec; 37(12):934-9. PubMed ID: 16243592 [TBL] [Abstract][Full Text] [Related]
18. Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome. van der Veek PP; van Rood YR; Masclee AA Aliment Pharmacol Ther; 2007 Sep; 26(6):943-52. PubMed ID: 17767479 [TBL] [Abstract][Full Text] [Related]
19. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis: The treatment of irritable bowel syndrome. Lesbros-Pantoflickova D; Michetti P; Fried M; Beglinger C; Blum AL Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1253-69. PubMed ID: 15606387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]